Welcome to our dedicated page for Opus Genetics news (Ticker: IRD), a resource for investors and traders seeking the latest updates and insights on Opus Genetics stock.
Opus Genetics, Inc. develops ophthalmic therapies for inherited retinal diseases as a clinical-stage biopharmaceutical company. Its pipeline includes AAV-based gene therapy programs led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1 and MERTK.
Company news commonly covers clinical and preclinical data, FDA regulatory interactions, scientific conference presentations, financing arrangements and annual financial results. Updates also include ophthalmic small-molecule development tied to Phentolamine Ophthalmic Solution 0.75% and collaboration activity related to that asset.
Opus Genetics (Nasdaq: IRD) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved stock options for ten new non-executive employees under the 2021 Inducement Plan.
The options cover an aggregate 698,000 shares, are priced at fair market value on the grant date, and vest over four years, with 25% after one year and the remainder quarterly, subject to possible acceleration or forfeiture.
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.
A live and archived webcast will be available in the Investors > Events section of the company website.
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET.
A live and archived webcast will be available via the Investors > Events section of the Opus Genetics website.
Opus Genetics (Nasdaq: IRD) reported Q1 2026 results and key pipeline milestones. License and collaboration revenue was $2.2 million, with a net loss of $65.5 million ($0.75/share). Cash and equivalents total about $90 million, with a runway projected into 2029 supported by a $35 million senior notes financing and a planned $5 million equity investment from Oberland Capital.
Clinically, LCA5 showed six‑month pediatric gains of ~1.5 log unit in cone sensitivity and FDA RDEP acceptance, with a pivotal Phase 3 trial preparing to dose in Q4 2026. BEST1 Cohort 1 topline data are expected in September 2026, and RDH12, MERTK, and RHO programs are slated to enter the clinic over the next 12–18 months.
Opus Genetics (Nasdaq: IRD) reported ARVO 2026 clinical and preclinical data showing early functional gains across multiple inherited retinal disease programs. Six-month pediatric LCA5 data show >30-fold cone sensitivity improvements and visual-acuity gains. BEST1 adult data show up to 12-letter acuity improvement and ~23% central subfield thickness reduction. RHO programs report durable retinal preservation and a mutation-independent AAV approach advancing toward clinical translation.
Opus Genetics (NASDAQ: IRD) completed enrollment in Cohort 1 of its Phase 1/2 study of OPGx-BEST1, enrolling five adults with Best disease (three BVMD, two ARB). Four participants have been dosed and one is scheduled for dosing this month. Baseline demographics were presented at ARVO and three-month topline results for the full cohort are expected in September 2026.
ARVO materials and a summary video are available on the company website. Planned outcomes include OCT, microperimetry, BCVA, low-luminance acuity and contrast sensitivity.
Opus Genetics (Nasdaq: IRD) announced that its investigational LCA5 gene therapy, OPGx-LCA5, was accepted into the FDA's Rare Disease Evidence Principles (RDEP) program on May 4, 2026. RDEP acceptance enables early FDA collaboration on regulatory strategy, trial design, evidence generation, and evaluation frameworks for ultra-rare diseases.
The program covers approaches to demonstrating clinical benefit in small populations and may allow a single adequate and well-controlled study supported by confirmatory evidence as part of a potential approval pathway.
Opus Genetics (Nasdaq: IRD) announced that leadership will present program updates at multiple ophthalmology and gene‑therapy conferences in May 2026, including ARVO (May 3–7), ASGCT (May 11–15), Retina World Congress (May 14–17) and the Retinal Therapeutics Innovation Summit (May 1).
Presentations will cover preliminary Phase 1b/2a OPGx-BEST1 clinical data, preclinical OPGx-RHO work, and translational assays advancing their inherited retinal disease pipeline.
Opus Genetics (NASDAQ: IRD) will present three abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, 2026. Presentations include full Phase 3 VEGA-3 results for phentolamine 0.75% in presbyopia, a post-hoc MIRA-2 optical-impact analysis of RYZUMVI, and an encore LYNX-2 mesopic-vision study.
Opus noted a Viatris-funded educational symposium on April 11; Viatris holds exclusive U.S. commercialization rights under a global license for phentolamine 0.75%.
Opus Genetics (Nasdaq: IRD) secured a strategic financing facility with Oberland Capital that provides up to $155 million of primarily non-dilutive capital, including an $35 million initial tranche and a concurrent $5 million equity investment at $4.48 per share.
With ~$100 million pro forma cash, Opus says this extends runway into 2029 to complete pivotal OPGx-LCA5 and OPGx-BEST1 studies and to advance three earlier-stage programs toward clinical testing in 2026–2027.